<DOC>
	<DOC>NCT00002022</DOC>
	<brief_summary>The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.</brief_summary>
	<brief_title>Treatment Program for Anemia in AIDS Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition: Patients with the following are excluded: Life expectancy &lt; 3 months. = or &lt; grade 4 performance score. AIDSrelated dementia. Uncontrolled hypertension. Acute symptomatic opportunistic infection or other AIDSdefining illness. Patients with the following are excluded: Life expectancy &lt; 3 months. = or &lt; grade 4 performance score. AIDSrelated dementia. Uncontrolled hypertension. Acute symptomatic opportunistic infection or other AIDSdefining illness. Patients must have: A clinical diagnosis of AIDS. Hematocrit &lt; 30 percent. Endogenous serum erythropoietin level = or &lt; 500 U/ml. A life expectancy = or &gt; 3 months. &gt; Grade 4 performance score.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1991</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Drugs, Investigational</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Anemia</keyword>
	<keyword>Zidovudine</keyword>
</DOC>